Search Results - "Akkoç, Nihan"

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors by Yalnız, Fevzi Fırat, Akkoç, Nihan, Salihoğlu, Ayşe, Ar, M Cem, Öngören, Şeniz, Eşkazan, A Emre, Soysal, Teoman, Aydın, Yıldız

“…Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor…”
Get full text

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Kılıçkap, Saadettin, Atcı, Muhammed Mustafa, Kahraman, Seda, Keskinkılıç, Merve, Bilgetekin, İrem, Ayhan, Murat, Tural, Deniz, Eren, Önder, Akkoç Mustafayev, Fatma Nihan, Yaman, Şebnem, Tatlı, Ali Murat, Bayram, Ertuğrul, Kutlu, Yasin, Ertürk, İsmail, Özcan, Erkan, Gülmez, Ahmet, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, İriağaç, Yakup, Baytemür, Naziyet Köse, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Selçukbiricik, Fatih, Ergün, Yakup, Korkmaz, Taner, Ak, Naziye, Ünal, Çağlar, Akdeniz, Nadiye, Özgün, Mehmet Alpaslan, Öksüzoğlu, Berna, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. This retrospective trial included…”
Get full text

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study) by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Atcı, Muhammed Mustafa, Kahraman, Seda, Kılıçkap, Saadettin, Güven, Deniz Can, Keskinkılıç, Merve, Ayhan, Murat, Eren, Önder, Mustafayev, Fatma Nihan Akkoç, Yaman, Şebnem, Bayram, Ertuğrul, Ertürk, İsmail, Özcan, Erkan, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, Baytemür, Naziyet Köse, Gülmez, Ahmet, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Tatlı, Ali Murat, Ergün, Yakup, Ak, Naziye, Ünal, Çağlar, Özgün, Mehmet Alpaslan, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced…”
Get full text

Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention by Akkoc Mustafayev, Fatma Nihan, Liu, Diane D, Gutierrez, Angelica M, Lewis, John E, Ibrahim, Nuhad K, Valero, Vicente, Booser, Daniel J, Litton, Jennifer K, Koenig, Kimberly, Yu, Dihua, Sneige, Nour, Arun, Banu K

“…Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to…”
Get full text

Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations by Akkoc Mustafayev, Fatma Nihan, Shukla, Mihir Amitabh, Lanier, Amanda, Milton, Denái R., Gutierrez, Angelica M., Gruschkus, Stephen K., Lewis, John E., Murthy, Rashmi K., Arun, Banu K.

“…Background Breast cancer (BC) with germline BRCA1/2 mutations and their association with triple‐negative BC has been thoroughly investigated. However, some…”
Get full text

Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib by Iriagac, Yakup, Cavdar, Eyyup, Karaboyun, Kubilay, Tacar, Seher Yildiz, Akkoc Mustafayev, Fatma Nihan, Celik, Emir, Avci, Okan, Okutur, Sadi Kerem, Koral, Lokman, Demirci, Nebi Serkan, Ozgun, Alpaslan, Seber, Erdogan Selcuk

“…Crizotinib is a tyrosine kinase inhibitor used in patients with non-small cell lung cancer, and there are uncertainties about its effect on kidney function. In…”
Get full text

Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study by Esatoglu, Sinem Nihal, Akkoc-Mustafayev, Fatma Nihan, Ozguler, Yesim, Ozbakır, Fatma, Nohut, Okan K, Cevirgen, Dilsen, Hamuryudan, Vedat, Hatemi, Ibrahim, Celik, Aykut Ferhat, Yazici, Hasan, Hatemi, Gulen

“…Immunogenicity of tumor necrosis factor alpha inhibitors (TNFis) has been recognized as an important problem that may cause loss of efficacy and adverse events…”
Get full text

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors by Yalnız, Fevzi Fırat, Akkoç, Nihan, Salihoğlu, Ayşe, Ar, M. Cem, Aydın, Seniz, Eşkazan, A. Emre, Soysal, Teoman, Aydın, Yıldız

Get full text

Prognostic value of expression levels of miR‑148a, miR‑152 and HLA‑G in colon cancer by Emirzeoglu, Levent, Olmez, Ozgur, Mustafayev, Fatma Nihan Akkoc, Berber, Ufuk, Yilmaz, Ismail, Celik, Serkan, Oven, Bala Basak, Ozgun, Mehmet Alpaslan

“…Aberrant expression of human leukocyte antigen G (HLA-G), an immunosuppressive molecule, has been observed in various cancer types. The exact mechanism of…”
Get full text

Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience by Akkoc Mustafayev, Fatma Nihan, Munsell, Mark, Gutierrez-Barrera, Angelica M., Yam, Clinton, Layman, Rachel M., Arun, Banu

“…10587 Background: About 5-10% of breast cancers (BC) are related to germline BRCA 1/2 pathogenic variants (PV). Several studies have demonstrated the…”
Get full text